Skip to main content

Press shift tab to select search category

Loading...

Media
- Media
- Press Releases
Investors
Partnering
Careers

Press shift tab to select search category

Loading...
United States
< Back
- Global
- Annual Report
United States

Brazil

Canada

Mexico

Australia

China

Singapore

South Korea

Japan

Belgium

Ukraine

UK

Germany

France

Nordics

Greece

Italy

Netherlands

Spain

Poland

Russia

Czech Republic

Switzerland

Austria

Home
Company
Science
Responsibility
Patients
Stories

Study Indication: Neuroendocrine Tumors In Lung

Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours

IPN price

€97.70

€-0.65 (-0.66%)

Media
Investors
Partnering
Contact us

Leadership
Responsibility
Patients
Stories

Compliance
U.S. State Pricing Disclosures
Vigilance Alert: Identity Theft

Terms of Use
Privacy
Consumer Health Data Privacy
Cookies
Your Privacy Choices

© Ipsen Biopharmaceuticals, Inc. All rights reserved - 2025

You are now leaving the Ipsen US website. To continue, please click on continue.